REV3L, the catalytic subunit of DNA polymerase ζ, is involved in the progression and chemoresistance of esophageal squamous cell carcinoma

Zhu,Xiaozhong; Zou,Shitao; Zhou,Jundong; Zhu,Hongsheng; Zhang,Shuyu; Shang,Zengfu; Ding,Wei-Qun; Wu,Jinchang; Chen,Yihong

doi:10.3892/or.2016.4549

REV3L, the catalytic subunit of DNA polymerase ζ, is involved in the progression and chemoresistance of esophageal squamous cell carcinoma

Authors:
- Xiaozhong Zhu
- Shitao Zou
- Jundong Zhou
- Hongsheng Zhu
- Shuyu Zhang
- Zengfu Shang
- Wei-Qun Ding
- Jinchang Wu
- Yihong Chen
View Affiliations

Affiliations: Department of Radio-Oncology, Nanjing Medical University Affiliated Suzhou Hospital, Suzhou, Jiangsu 215001, P.R. China, Suzhou Cancer Center Core Laboratory, Suzhou, Jiangsu 215001, P.R. China, Department of Clinical Laboratory, Nanjing Medical University Affiliated Suzhou Hospital, Suzhou, Jiangsu 215001, P.R. China, School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, Jiangsu 215123, P.R. China, Department of Pathology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA, Department of Radio-Oncology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui 241001, P.R. China
Published online on: January 5, 2016 https://doi.org/10.3892/or.2016.4549
Pages: 1664-1670

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protein reversionless 3-like (REV3L), the catalytic subunit of DNA polymerase (pol) ζ, is well known to participate in error-prone translesion synthesis (TLS) with less stringent and lower processivity. Recent evidence has demonstrated that REV3L is involved in carcinogenesis and tumor progression. However, the function of REV3L remains unclear in esophageal squamous cell carcinoma (ESCC). In the present study, we examined REV3L expression in ESCC tissues and its association with clinicopathological parameters. REV3L was found to be significantly upregulated and correlated with lymph node metastasis and clinical stage in the ESCC tissues. To further investigate the potential role of REV3L in esophageal cancer, stable ESCC cell lines with suppression of REV3L expression were established. Downregulation of REV3L expression led to a decrease in cell proliferation and invasive capacity partly through suppression of cyclin D1 and survivin expression, and an increase in cellular sensitivity to 5-fluorouracil (5-FU) by induction of G1 phase arrest and apoptosis. Therefore, REV3L plays an important role in ESCC progression and chemoresistance, and is a potential diagnostic marker and therapeutic target for ESCC.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar : PubMed/NCBI
2	Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
3	Talukdar FR, Ghosh SK, Laskar RS and Mondal R: Epigenetic, genetic and environmental interactions in esophageal squamous cell carcinoma from northeast India. PLoS One. 8:e609962013. View Article : Google Scholar : PubMed/NCBI
4	Friedberg EC: A history of the DNA repair and mutagenesis field: I. The discovery of enzymatic photoreactivation. DNA Repair. 33:35–42. 2015. View Article : Google Scholar : PubMed/NCBI
5	Gan GN, Wittschieben JP, Wittschieben BO and Wood RD: DNA polymerase zeta (pol ζ) in higher eukaryotes. Cell Res. 18:174–183. 2008. View Article : Google Scholar
6	Knobel PA, Kotov IN, Felley-Bosco E, Stahel RA and Marti TM: Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells. Neoplasia. 13:961–970. 2011. View Article : Google Scholar : PubMed/NCBI
7	Zhang S, Chen H, Zhao X, Cao J, Tong J, Lu J, Wu W, Shen H, Wei Q and Lu D: REV3L 3′UTR 460 T>C polymorphism in microRNA target sites contributes to lung cancer susceptibility. Oncogene. 32:242–250. 2013. View Article : Google Scholar
8	Varadi V, Bevier M, Grzybowska E, Johansson R, Enquist K, Henriksson R, Butkiewicz D, Pamula-Pilat J, Tecza K, Hemminki K, et al: Genetic variation in genes encoding for polymerase ζ subunits associates with breast cancer risk, tumour characteristics and survival. Breast Cancer Res Treat. 129:235–245. 2011. View Article : Google Scholar : PubMed/NCBI
9	Yang L, Shi T, Liu F, Ren C, Wang Z, Li Y, Tu X, Yang G and Cheng X: REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells. PLoS One. 10:e01203342015. View Article : Google Scholar : PubMed/NCBI
10	Shi TY, Yang L, Yang G, Tu XY, Wu X, Cheng X and Wei Q: DNA polymerase ζ as a potential biomarker of chemoradiation resistance and poor prognosis for cervical cancer. Med Oncol. 30:5002013. View Article : Google Scholar
11	Kawamura K, O-Wang J, Bahar R, Koshikawa N, Shishikura T, Nakagawara A, Sakiyama S, Kajiwara K, Kimura M and Tagawa M: The error-prone DNA polymerase ζ catalytic subunit (Rev3) gene is ubiquitously expressed in normal and malignant human tissues. Int J Oncol. 18:97–103. 2001.
12	Xiao W, Lechler T, Chow BL, Fontanie T, Agustus M, Carter KC and Wei YF: Identification, chromosomal mapping and tissue-specific expression of hREV3 encoding a putative human DNA polymerase ζ. Carcinogenesis. 19:945–949. 1998. View Article : Google Scholar : PubMed/NCBI
13	Brondello JM, Pillaire MJ, Rodriguez C, Gourraud PA, Selves J, Cazaux C and Piette J: Novel evidences for a tumor suppressor role of Rev3, the catalytic subunit of Pol ζ. Oncogene. 27:6093–6101. 2008. View Article : Google Scholar : PubMed/NCBI
14	Wang H, Zhang SY, Wang S, Lu J, Wu W, Weng L, Chen D, Zhang Y, Lu Z, Yang J, et al: REV3L confers chemoresistance to cisplatin in human gliomas: The potential of its RNAi for synergistic therapy. Neuro Oncol. 11:790–802. 2009. View Article : Google Scholar : PubMed/NCBI
15	Zhou J, Zhang S, Xie L, Liu P, Xie F, Wu J, Cao J and Ding WQ: Overexpression of DNA polymerase iota (Polι) in esophageal squamous cell carcinoma. Cancer Sci. 103:1574–1579. 2012. View Article : Google Scholar : PubMed/NCBI
16	Waters LS, Minesinger BK, Wiltrout ME, D'Souza S, Woodruff RV and Walker GC: Eukaryotic translesion polymerases and their roles and regulation in DNA damage tolerance. Microbiol Mol Biol Rev. 73:134–154. 2009. View Article : Google Scholar : PubMed/NCBI
17	Gibbs PE, McGregor WG, Maher VM, Nisson P and Lawrence CW: A human homolog of the Saccharomyces cerevisiae REV3 gene, which encodes the catalytic subunit of DNA polymerase ζ. Proc Natl Acad Sci USA. 95:6876–6880. 1998. View Article : Google Scholar
18	Gueranger Q, Stary A, Aoufouchi S, Faili A, Sarasin A, Reynaud CA and Weill JC: Role of DNA polymerases η, ι and ζ in UV resistance and UV-induced mutagenesis in a human cell line. DNA Repair. 7:1551–1562. 2008. View Article : Google Scholar
19	Hicks JK, Chute CL, Paulsen MT, Ragland RL, Howlett NG, Guéranger Q, Glover TW and Canman CE: Differential roles for DNA polymerases eta, zeta, and REV1 in lesion bypass of intrastrand versus interstrand DNA cross-links. Mol Cell Biol. 30:1217–1230. 2010. View Article : Google Scholar :
20	Sarbia M, Stahl M, Fink U, Heep H, Dutkowski P, Willers R, Seeber S and Gabbert HE: Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int J Cancer. 84:86–91. 1999. View Article : Google Scholar : PubMed/NCBI
21	Diehl JA: Cycling to cancer with cyclin D1. Cancer Biol Ther. 1:226–231. 2002. View Article : Google Scholar : PubMed/NCBI
22	Jares P, Colomer D and Campo E: Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics. Nat Rev Cancer. 7:750–762. 2007. View Article : Google Scholar : PubMed/NCBI
23	Thomas GR, Nadiminti H and Regalado J: Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol. 86:347–363. 2005. View Article : Google Scholar : PubMed/NCBI
24	Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008. View Article : Google Scholar
25	Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J, et al: Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy. Int J Cancer. 95:92–95. 2001. View Article : Google Scholar : PubMed/NCBI
26	Wang L, Feng J, Chen X, Guo W, Du Y, Wang Y, Zang W, Zhang S and Zhao G: Myricetin enhance chemosensitivity of 5-fluorouracil on esophageal carcinoma in vitro and in vivo. Cancer Cell Int. 14:712014. View Article : Google Scholar : PubMed/NCBI
27	Pinedo HM and Peters GF: Fluorouracil: Biochemistry and pharmacology. J Clin Oncol. 6:1653–1664. 1988.PubMed/NCBI
28	Bijnsdorp IV, Peters GJ, Temmink OH, Fukushima M and Kruyt FA: Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells. Int J Cancer. 126:2457–2468. 2010.